80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]林慧,陳佳菁,陳燕紅,等.高危型HPV檢測(cè)和TCT在宮頸癌前病變篩查中的應(yīng)用價(jià)值股骨頭中心與鄰近骨性標(biāo)志關(guān)系的研究[J].福建醫(yī)藥雜志,2022,44(05):21-24.
　LIN Hui,CHEN Jiajing,CHEN Yanhong,et al.Application value of high-risk HPV detection and TCT in screening cervical precancerous lesions[J].FUJIAN MEDICAL JOURNAL,2022,44(05):21-24.
點(diǎn)擊復(fù)制

高危型HPV檢測(cè)和TCT在宮頸癌前病變篩查中的應(yīng)用價(jià)值股骨頭中心與鄰近骨性標(biāo)志關(guān)系的研究()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
44
期數(shù):
2022年05期
頁(yè)碼:
21-24
欄目:
臨床研究
出版日期:
2022-10-15

文章信息/Info

Title:
Application value of high-risk HPV detection and TCT in screening cervical precancerous lesions
文章編號(hào):
1002-2600（2022）05-0021-04
作者:
林慧; 陳佳菁; 陳燕紅; 邱建龍
中國(guó)人民解放軍聯(lián)勤保障部隊(duì)第910醫(yī)院病理科（泉州 362000）
Author(s):
LIN Hui; CHEN Jiajing; CHEN Yanhong; QIU Jianlong
Department of Pathology, the 910th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Quanzhou, Fujian 362000, China
關(guān)鍵詞:
人乳頭瘤病毒; 液基細(xì)胞學(xué); 宮頸癌前病變; 應(yīng)用價(jià)值
Keywords:
human papillomavirus;  liquid based cytology;  cervical precancerous lesions;  application value
分類號(hào):
R737.33
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 探討高危型人乳頭瘤病毒（HR-HPV）檢測(cè)和液基薄層細(xì)胞學(xué)檢查（TCT）在宮頸癌前病變篩查中的應(yīng)用價(jià)值。 方法 回顧性分析2018年1月至2020年12月我院的宮頸癌篩查資料。選取15 162名進(jìn)行TCT和HR-HPV聯(lián)合篩查的人員作為研究對(duì)象，包括體檢11 831例，婦科患者3 331例，了解福建泉州地區(qū)不同人群HR-HPV的感染狀況。另外選取1 220例TCT、1 428例HR-HPV檢測(cè)以及843例聯(lián)合篩查數(shù)據(jù)，以宮頸活檢結(jié)果為標(biāo)準(zhǔn)，比較不同篩查方法對(duì)宮頸鱗癌前驅(qū)病變的篩查效能。 結(jié)果 HR-HPV的檢出率隨著組織學(xué)病變級(jí)別的升高而增高。以宮頸活檢結(jié)果為標(biāo)準(zhǔn)，HR-HPV檢測(cè)篩查宮頸鱗狀上皮內(nèi)病變的靈敏度為94.2%，特異度為66.2%；TCT篩查的靈敏度為79.9%，特異度為86.8%；兩種方法聯(lián)合篩查的靈敏度為97.4%，特異度為58.2%。 結(jié)論 HR-HPV檢測(cè)具有高靈敏度，更適合用于宮頸癌前病變的初篩。TCT特異性較高，適合作為HPV陽(yáng)性人員的分流方法或與HR-HPV檢測(cè)聯(lián)合應(yīng)用。
Abstract:
Objective To explore the application value of high-risk human papillomavirus (HR-HPV) detection and thinprep cytology test (TCT) in the screening of cervical precancerous lesions. Methods The screening data of cervical cancer in our hospital from January 2018 to December 2020 were retrospectively analyzed.A total of 15 162 cases who underwent TCT and HR-HPV combined screening were selected as the research objects, including 11 831 physical examinations and 3 331 gynecological patients, to understand the infection status of HR-HPV in different populations in Quanzhou, Fujian province.In addition, 1 220 cases of TCT, 1 428 cases of HR-HPV detection and 843 cases of combined screening data were selected, and the screening efficacy of different screening methods for cervical squamous cell carcinoma precursor lesions were compared with the results of cervical biopsy. Results The detection rate of HR-HPV increased with the increase of histological grade.Based on the results of cervical biopsy, the sensitivity and specificity of HR-HPV detection in screening cervical squamous intraepithelial lesions were 94.2% and 66.2%, respectively. The sensitivity and specificity of TCT screening were 79.9% and 86.8%, respectively.The sensitivity and specificity of the combined screening method were 97.4% and 58.2%, respectively.Conclusion HR-HPV detection is more suitable for the primary screening of cervical precancerous lesions due to its high sensitivity.TCT has high specificity and is suitable for using as a shunt method for HPV positive persons or in combination with HR-HPV detection.

參考文獻(xiàn)/References:

[1] Berman T A，Schiller J T.Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases[J].Cancer，2017，123（12）：2219-2229.
[2] Chrysostomou A C，Stylianou D C，Constantinidou A，et al.Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing[J].Viruses，2018，10（12）：729-763.
[3] 王華慶，王巖，王朝華，等.子宮頸癌等人乳頭瘤病毒相關(guān)疾病免疫預(yù)防專家共識(shí)(簡(jiǎn)版)[J].中國(guó)病毒病雜志，2019，9（6）：401-418.
[4] Zhao X，Wu Q，Wang X，et al.The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women[J].Clin Microbiol Infect，2018，24（12）：1322-1327.
[5] Bhatla N，Singhal S.Primary HPV screening for cervical cancer[J].Best Pract Res Clin Obstet Gynaecol，2020，65：98-108.
[6] Maver P J，Poljak M.Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans[J].Clin Microbiol Infect，2020，26（5）：579-583.
[7] Tota J E，Bentley J，Blake J，et al.Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening[J].Prev Med，2017，98：15-20.
[8] 魏麗惠，趙昀，沈丹華，等.中國(guó)子宮頸癌篩查及異常管理相關(guān)問(wèn)題專家共識(shí)(一)[J].中國(guó)婦產(chǎn)科臨床雜志，2017，18（2）：190-192.
[9] 沈丹華.重視子宮頸癌篩查及診治中病理醫(yī)師的作用[J].中華婦產(chǎn)科雜志，2019，54（1）：3-6.
[10] Casey S，Harley I，Jamison J，et al.A rare case of HPV-negative cervical squamous cell carcinoma[J].Int J Gynecol Pathol，2015，34（2）：208-212.
[11] Tracht J M，Davis A D，F(xiàn)asciano D N，et al.Discrepant HPV/cytology cotesting results: Are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia [J].Cancer Cytopathol，2017，125（10）：795-805.
[12] Blatt A J，Kennedy R，Luff R D，et al.Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices[J].Cancer Cytopathol，2015，123（5）：282-288.
[13] Bergeron C，Giorgi-Rossi P，Cas F，et al.Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial[J].J Natl Cancer Inst，2015，107（2）：423-429.
[14] 趙雪蓮，熱米拉·熱扎克，胡尚英，等.高危型HPV DNA單獨(dú)檢測(cè)及與薄層液基細(xì)胞學(xué)聯(lián)合篩查對(duì)宮頸癌及宮頸高度病變的篩查效果比較[J].中華預(yù)防醫(yī)學(xué)雜志，2018，52（5）：469-474.

相似文獻(xiàn)/References:

[1]林聯(lián)韻,高麗丹,吳莉春,等.永安市女性人乳頭瘤病毒感染和基因亞型分布特點(diǎn)[J].福建醫(yī)藥雜志,2017,39(4):100.
[2]吳敏強(qiáng).平潭地區(qū)男性高危人群人乳頭瘤病毒基因亞型檢測(cè)(附202例分析)[J].福建醫(yī)藥雜志,2017,39(5):73.
[3]黃 勉 林 珺 沈 張 金 瓊 陶 紅 吳三山 劉禹利.PAX1基因甲基化用于子宮頸癌臨床應(yīng)用價(jià)值探討[J].福建醫(yī)藥雜志,2020,42(03):3.
　HUANG Mian,LIN Jun,SHEN Zhang,et al.Clinical application value of methylated PAX1 gene in cervical cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(05):3.

更新日期/Last Update: 2022-10-15